Similar articles

• Allogeneic bone marrow transplantation without graft-v-host disease: true tolerance of graft against the host through depletion of donor T lymphocytes pregrafting in malignant and nonmalignant disorders.

  Slavin S, Or R, Naparstek E, Weiss L, Mumcuoglu M, Weshler Z, Brautbar H, Cividalli G, Glikson M, Hale G, et al. Slavin S, et al. Transplant Proc. 1987 Feb;19(1 Pt 3):2614-5. Transplant Proc. 1987. PMID: 3274569 No abstract available.
• Liver transplantation in Birmingham--use of cyclosporine--clinical correlations with drug measurements.

  Gunson BK, Jones SR, Buckels JA, Jain AB, McMaster P. Gunson BK, et al. Transplant Proc. 1990 Jun;22(3):1312-8. Transplant Proc. 1990. PMID: 2349692 No abstract available.
• Pharmacokinetic and pharmacodynamic studies of cyclosporine in bone marrow transplantation.

  Yee GC. Yee GC. Transplant Proc. 1990 Jun;22(3):1327-30. Transplant Proc. 1990. PMID: 2190394 Review. No abstract available.
• Bone marrow transplantation: past experiences and future prospects.

  Thomas ED. Thomas ED. Semin Oncol. 1992 Jun;19(3 Suppl 7):3-6. Semin Oncol. 1992. PMID: 1615331 Review. No abstract available.
• A multicenter, randomized, double-blind comparison of different doses of intravenous immunoglobulin for prevention of graft-versus-host disease and infection after allogeneic bone marrow transplantation.

  Winston DJ, Antin JH, Wolff SN, Bierer BE, Small T, Miller KB, Linker C, Kaizer H, Lazarus HM, Petersen FB, Cowan MJ, Ho WG, Wingard JR, Schiller GJ, Territo MC, Jiao J, Petrarca MA, Tonetta SA. Winston DJ, et al. Bone Marrow Transplant. 2001 Jul;28(2):187-96. doi: 10.1038/sj.bmt.1703109. Bone Marrow Transplant. 2001. PMID: 11509937 Clinical Trial.